Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.
The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses.
Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 20, 26 | -0.24 Increased by +4.00% | -0.22 Decreased by -9.94% |
| Nov 5, 25 | -0.21 Decreased by -10.53% | -0.22 Increased by +4.55% |
| Aug 7, 25 | -0.20 Increased by +9.09% | -0.22 Increased by +9.09% |
| May 6, 25 | -0.21 Increased by +27.59% | -0.22 Increased by +4.55% |
| Mar 28, 25 | -0.25 Increased by 0.00% | -0.25 |
| Nov 14, 24 | -0.19 Increased by +5.00% | -0.25 Increased by +24.00% |
| Aug 15, 24 | -0.22 Increased by +4.35% | -0.24 Increased by +8.33% |
| May 9, 24 | -0.29 Increased by +45.28% | -0.23 Decreased by -26.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 8.00 K Decreased by -99.11% | -9.25 M Decreased by -3.02% | Decreased by -115.59 K% Decreased by -11.44 K% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -7.95 M Decreased by -22.93% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -7.46 M Decreased by -13.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 452.00 K Increased by +5.55 K% | -7.49 M Increased by +4.56% | Decreased by -1.66 K% Increased by +98.31% |
| Dec 31, 24 | 896.00 K Decreased by -38.80% | -8.98 M Decreased by -32.64% | Decreased by -1.00 K% Decreased by -116.73% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -6.47 M Decreased by -20.99% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -6.58 M Decreased by -12.97% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 8.00 K Decreased by -95.29% | -7.85 M Increased by +24.26% | Decreased by -98.13 K% Decreased by -1.51 K% |